Lantern Pharma Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation TX
Business Address 1920 MCKINNEY AVENUE, DALLAS, TX, 75201
Mailing Address 1920 MCKINNEY AVENUE, DALLAS, TX, 75201
Phone 972-277-1136
Fiscal Year End 1231
EIN 463973463
Financial Overview
FY2025
-$17.12M
Net Income
$25.57M
Total Assets
$4.50M
Total Liabilities
$40.91M
Stockholders' Equity
$-1.57
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 30, 2026 | View on SEC |
| 424B5 Prospectus supplement | March 30, 2026 | View on SEC |
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | February 23, 2026 | View on SEC |
| 8-K Current report of material events | January 23, 2026 | View on SEC |
| 4 Insider stock transaction report | January 13, 2026 | View on SEC |
| 4 Insider stock transaction report | January 13, 2026 | View on SEC |
| 4 Insider stock transaction report | January 13, 2026 | View on SEC |
| 4 Insider stock transaction report | January 13, 2026 | View on SEC |
| 4 Insider stock transaction report | January 13, 2026 | View on SEC |
Annual Reports
10-K March 30, 2026
- FDA clearance for two Phase 1b/2 clinical trials for lead drug LP-184.
- Launch of withZeta.ai, a generative AI co-scientist that accelerates biomarker discovery.
Related Companies
Companies in the same industry (SIC: 2834)
NERVGEN PHARMA CORP.
NGEN Pharmaceutical Preparations
Connect Biopharma Holdings Ltd
CNTB Pharmaceutical Preparations
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
LIXT Pharmaceutical Preparations
TuHURA Biosciences, Inc./NV
HURA Pharmaceutical Preparations
Canton Strategic Holdings, Inc.
CNTN Pharmaceutical Preparations
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.